KLK3 Antibody

What is KLK3 and why is it an important research target?

KLK3, also known as Prostate Specific Antigen (PSA), is a 28.7 kDa serine protease encoded by the KLK3 gene in humans. The protein serves primarily as a biomarker for prostate cancer detection and monitoring, but also plays crucial physiological roles in semen liquefaction and male fertility. KLK3 functions by hydrolyzing semenogelin I, a major protein in seminal plasma, allowing sperm to swim freely after ejaculation . Beyond its diagnostic value in prostate cancer, emerging research indicates KLK3 involvement in lymphangiogenesis through activation of vascular endothelial growth factors, making it a multifaceted research target with clinical and biological significance .

What are the major types of KLK3 antibodies available for research applications?

KLK3 antibodies are available in multiple formats optimized for different research applications. Monoclonal antibodies, such as A67-B/E3 and LT3D2, provide high specificity for human KLK3 across Western blotting, immunoprecipitation, immunofluorescence, and ELISA applications . Polyclonal antibodies like CAB2052 recognize multiple epitopes, providing potentially enhanced sensitivity for certain applications . Premium antibodies designated with quality indicators (e.g., Boster Bio's "Picoband") guarantee superior performance with minimal background in Western blot applications . KLK3 antibodies are available unconjugated or with diverse conjugates including horseradish peroxidase, phycoerythrin, fluorescein isothiocyanate, biotin, and various fluorophores (Alexa Fluor, Cy3, Dylight488), allowing researchers to select optimal formats for their specific experimental requirements .

How do monoclonal and polyclonal KLK3 antibodies differ in their research applications?

Monoclonal and polyclonal KLK3 antibodies offer distinct advantages depending on the research application. Monoclonal antibodies like A67-B/E3 recognize a single epitope, providing exceptional specificity when particular forms of KLK3 must be distinguished . This property makes them ideal for discriminating between free PSA and PSA bound to protease inhibitors, which is critical in clinical diagnostics and certain research paradigms. Conversely, polyclonal antibodies such as CAB2052 recognize multiple epitopes across the KLK3 protein, offering potentially greater sensitivity for detecting denatured proteins in Western blots or fixed samples in immunohistochemistry .

For applications requiring detection of KLK3 across multiple species, certain antibodies demonstrate cross-reactivity. For instance, the KLK3 antibody from Aviva Systems Biology reacts with human, mouse, rat, and dog samples, while CAB2052 shows reactivity with human and mouse samples . When selecting between monoclonal and polyclonal antibodies, researchers should consider the nature of their experimental system, required specificity level, antigen state (native versus denatured), and cross-reactivity requirements among species.

What are the optimal sample preparation protocols for KLK3 Western blotting?

Successful Western blot detection of KLK3 requires meticulous sample preparation. According to validated protocols, electrophoresis should be performed on a 5-20% SDS-PAGE gradient gel at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours . Each sample well should be loaded with approximately 30 μg of protein under reducing conditions. Following electrophoresis, proteins should be transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes .

The blocking procedure is critical: membranes should be blocked with 5% non-fat milk in TBS for 1.5 hours at room temperature to minimize non-specific binding. For primary antibody incubation, use affinity purified anti-KLK3 antibody at an optimized concentration (e.g., 0.5 μg/mL for PB9259) and incubate overnight at 4°C . After thorough washing with TBS-0.1% Tween (three times, 5 minutes each), probe with an appropriate HRP-conjugated secondary antibody at a dilution of 1:5000 for 1.5 hours at room temperature. Signal development using Enhanced Chemiluminescent detection systems will reveal KLK3 at approximately 29 kDa, which corresponds to the expected molecular weight of the protein .

How should immunohistochemistry protocols be optimized for KLK3 detection?

Optimizing immunohistochemistry (IHC) for KLK3 detection requires attention to several critical parameters. For paraffin-embedded sections of prostatic tissues, heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is essential to unmask epitopes . After antigen retrieval, tissue sections should be blocked with 10% goat serum to reduce non-specific binding. Primary antibody incubation parameters vary by antibody - PB9259 has been successfully used at 2 μg/ml concentration with overnight incubation at 4°C, while CAB2052 is recommended at dilutions between 1:50 and 1:200 .

For detection systems, biotinylated secondary antibodies (incubated for 30 minutes at 37°C) followed by Strepavidin-Biotin-Complex (SABC) with DAB as the chromogen provide excellent visualization of KLK3 in prostatic epithelium . For fluorescence-based detection, multiple antibodies are available with direct fluorescent conjugates, eliminating the need for secondary antibodies. Researchers should always include appropriate positive controls (prostatic cancer tissue) and negative controls (tissues known to lack KLK3 expression such as seminal vesicles and urethra) to validate staining specificity .

What controls are essential for validating KLK3 antibody specificity?

Validating KLK3 antibody specificity requires comprehensive controls across different experimental platforms. For Western blot applications, positive controls should include lysates from LNCaP or LNCaP-AR cell lines, which are established models of KLK3-expressing prostate cancer . For immunohistochemistry, prostatic cancer tissue serves as an appropriate positive control, while tissues lacking KLK3 expression (such as seminal vesicles and urethra) provide excellent negative controls .

For blocking studies demonstrating binding specificity, unlabeled antibodies can be used for competitive inhibition. In radiolabeled antibody studies, co-administration of unlabeled hu5A10 with [89Zr]hu5A10 verified targeting specificity . When evaluating novel tissues or cellular systems, researchers should compare reactivity patterns across anatomical regions with known differential KLK3 expression. In transgenic models like KLK3_Hi-Myc mice, ventral prostate lobes typically show higher KLK3 expression than anterior and dorsolateral lobes, providing an internal biological validation system .

Beyond these application-specific controls, researchers should consider antibody validation through genetic approaches (knockdown/knockout models), cross-validation with multiple antibodies targeting different epitopes, and correlation with mRNA expression data to conclusively establish antibody specificity.

How are KLK3 antibodies enabling theranostic approaches in prostate cancer research?

KLK3 antibodies are revolutionizing theranostic (combined therapeutic and diagnostic) approaches in prostate cancer research through the development of targeted radioimmunoconjugates. The humanized monoclonal antibody hu5A10, which specifically targets free PSA, has demonstrated remarkable potential in preclinical studies . This antibody has been successfully conjugated with different radioisotopes to serve complementary functions - diagnostic imaging ([89Zr]hu5A10) and therapeutic intervention ([90Y]hu5A10 and [225Ac]hu5A10) .

In imaging applications, [89Zr]hu5A10 shows specific tumor uptake that increases over time and correlates with PSA expression levels. PET imaging allows visualization of PSA-expressing tissues in both mouse models and non-human primates over extended observation periods (up to 2 weeks), proving the stability and specificity of this imaging approach . For therapeutic applications, treatment with both [90Y]hu5A10 (beta-emitter) and [225Ac]hu5A10 (alpha-emitter) effectively reduced tumor burden and prolonged survival in preclinical models .

Interestingly, these radioisotopes exhibited different therapeutic profiles: [90Y]hu5A10 showed more immediate effects but less sustained response, while [225Ac]hu5A10 demonstrated more durable tumor control with higher rates of complete response (7/18 mice with [225Ac]hu5A10 versus 1/9 mice with [90Y]hu5A10) . These preclinical studies provide strong support for the clinical translation of radiolabeled hu5A10 as a theranostic platform for prostate cancer management, particularly in cases where resistance to conventional androgen receptor-targeting therapies has developed .

How can KLK3 antibodies be used to study the interaction between androgen receptor signaling and PSA expression?

KLK3 antibodies provide powerful tools for investigating the intricate relationship between androgen receptor (AR) signaling and PSA expression, particularly in the context of prostate cancer treatment resistance. Since KLK3 is an androgen-regulated gene, its expression serves as a functional readout of AR activity . This relationship becomes especially significant in prostate cancer, where most patients treated with AR-signaling inhibitors eventually develop therapeutic resistance due to restoration of AR functionality .

For studying these interactions, researchers have developed specialized experimental models, including the LNCaP-AR cell line (LNCaP with overexpression of wildtype AR) and KLK3_Hi-Myc transgenic mice . These models allow investigation of enhanced AR signaling effects on KLK3 expression. Using antibody-based detection methods, researchers can quantify PSA protein levels in response to AR modulation via Western blotting, while immunohistochemistry reveals the spatial distribution of PSA expression in AR-manipulated tissues .

Advanced applications involve using radiolabeled KLK3 antibodies like hu5A10 for "downstream targeting of AR in PSA-expressing tissue," providing a novel therapeutic approach to address AR-signaling inhibitor resistance . By monitoring KLK3 expression as a functional readout of restored AR activity, researchers can evaluate mechanisms of castration resistance and develop targeted interventions. This approach is particularly valuable for understanding how AR signaling persists despite androgen deprivation, often through alternative pathways or AR mutations that enable continued KLK3 expression even in hormone-depleted environments.

How can non-specific binding be reduced when using KLK3 antibodies?

Minimizing non-specific binding is crucial for generating reliable results with KLK3 antibodies. For Western blot applications, optimizing blocking conditions is essential - using 5% non-fat milk in TBS for 1.5 hours at room temperature effectively saturates non-specific protein binding sites on nitrocellulose membranes . Proper antibody dilution optimization significantly impacts specificity; for example, PB9259 works optimally at 0.5 μg/mL concentration, while CAB2052 performs best at 1:500-1:1000 dilution for Western blotting .

Thorough washing protocols using TBS with 0.1% Tween-20 (three repetitions of 5-minute washes) effectively remove unbound or loosely bound antibodies that contribute to background signal . Using high-quality antibodies designated as premium products (such as Boster Bio's "Picoband®") can ensure "superior quality, high affinity, and strong signals with minimal background" .

For immunohistochemistry applications, background reduction strategies include using 10% goat serum as a blocking agent, selecting secondary antibodies raised against the appropriate host species immunoglobulin, and careful titration of primary antibodies to find the optimal working concentration . Researchers should also consider advanced techniques such as pre-adsorbing antibodies with non-specific proteins or using more stringent washing buffers for particularly challenging applications requiring exceptional signal-to-noise ratios.

What strategies can resolve issues with detecting KLK3 in samples with low expression levels?

Detecting KLK3 in samples with low expression levels requires specialized approaches to enhance sensitivity while maintaining specificity. Signal amplification methods represent a primary strategy - using Strepavidin-Biotin-Complex (SABC) with DAB as chromogen for immunohistochemistry provides significant signal enhancement through the multiple biotin-streptavidin interactions . For Western blotting, Enhanced Chemiluminescent detection systems with extended exposure times can capture weak signals .

Alternative detection approaches include using radiolabeled antibody techniques ([89Zr]hu5A10, [90Y]hu5A10, [225Ac]hu5A10) which offer exceptional sensitivity for in vivo detection, or fluorescently conjugated antibodies (FITC, PE, Cy3, Dylight488) that may provide improved sensitivity over conventional chromogenic detection . Sample preparation enhancements also play a critical role - researchers can increase protein loading beyond standard protocols (30 μg) for Western blot applications or employ protein enrichment approaches like immunoprecipitation prior to analysis .

Optimizing antibody incubation conditions can significantly impact detection sensitivity - extended incubation times (overnight at 4°C) allow maximum antibody binding while minimizing background . For immunohistochemistry applications, optimized antigen retrieval using EDTA buffer (pH 8.0) ensures maximal epitope accessibility . Finally, antibody selection is crucial - polyclonal antibodies like CAB2052 might offer greater sensitivity by binding multiple epitopes compared to monoclonal alternatives when working with samples containing minimal KLK3 .

How are KLK3 antibodies being used to study PSA's role beyond prostate cancer?

KLK3 antibodies are instrumental in expanding our understanding of PSA's functions beyond its traditional role as a prostate cancer biomarker. One significant discovery revealed through antibody-based research is PSA's ability to activate vascular endothelial growth factors VEGF-C and VEGF-D . This function was verified using KLK3 antibodies like 5C7 to block activation, demonstrating the specificity of this interaction . Western blotting with anti-VEGF-C antisera detected both pro-VEGF-C and activated VEGF-C following KLK3 treatment, establishing PSA as a regulator of lymphangiogenic factors .

Antibodies are also facilitating investigation of PSA expression in tissues beyond the prostate. Research indicates PSA presence in breast tissue and other non-prostatic tissues, suggesting broader physiological roles . This extraprostatic expression is being characterized through immunohistochemistry, Western blotting, and flow cytometry using antibodies like A67-B/E3 and LT3D2 .

Beyond cancer research, KLK3 antibodies help elucidate PSA's physiological functions in "semen liquefaction and male fertility," where it "liquifies the semen in the seminal coagulum and allows sperm to swim freely" . By detecting PSA in relevant biological fluids and tissues, antibodies contribute to our understanding of reproductive physiology. These diverse applications demonstrate how KLK3 antibodies are expanding our concept of PSA from a simple biomarker to a multifunctional protein with roles in angiogenesis, lymphangiogenesis, and tissue remodeling.

What are the latest developments in targeted therapeutic approaches using KLK3 antibodies?

Recent advances in KLK3 antibody-based therapeutics center on radioimmunotherapy approaches using the humanized monoclonal antibody hu5A10, which specifically targets free PSA . This antibody has been developed as a versatile theranostic agent with three radiolabeled variations: [89Zr]hu5A10 for PET imaging (diagnostic component), [90Y]hu5A10 (beta-emitter) for therapy, and [225Ac]hu5A10 (alpha-emitter) for therapy .

Comprehensive preclinical evaluation has demonstrated significant therapeutic efficacy: "Treatment with [90Y]/[225Ac]hu5A10 effectively reduced tumor burden and prolonged survival (p≤0.0054)" . Interestingly, different radioisotopes exhibited distinct therapeutic profiles – [90Y]hu5A10 produced more immediate effects than [225Ac]hu5A10 but less sustained tumor control . Complete tumor responses were achieved in 7/18 mice treated with [225Ac]hu5A10 compared to 1/9 mice receiving [90Y]hu5A10, highlighting the superiority of alpha emission therapy for durable tumor control .

This approach represents a paradigm shift in PSA-targeting strategies by utilizing PSA as a direct therapeutic target rather than merely a biomarker. The continued expression of PSA even in castration-resistant disease makes this approach particularly valuable for patients who develop resistance to conventional AR-signaling inhibitors . Comprehensive preclinical validation in multiple model systems (LNCaP-AR xenografts, KLK3_Hi-Myc transgenic mice, and non-human primates) has generated compelling data supporting clinical translation of radiolabeled hu5A10 for treating prostate cancer .